Dyslipidaemia in the Middle East: Current status and a call for action

Khalid Al Rasadi, Wael Almahmeed, Khalid F. AlHabib, Marianne Abifadel, Hasan Ali Farhan, Saud AlSifri, Selim Jambart, Mohammad Zubaid, Zuhier Awan, Khalid Al-Waili, Philip Barter

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is among the highest in the world. The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its management in the ME region, and to propose initiatives to address the burden of dyslipidaemia. Published literature on the epidemiology of dyslipidaemia in the ME region was presented and discussed at an expert meeting that provided the basis of this review article. The high prevalence of metabolic syndrome, diabetes, familial hypercholesterolaemia (FH) and consanguineous marriages, in the ME region, results in a pattern of dyslipidaemia (low high-density lipoprotein cholesterol and high triglycerides) that is different from many other regions of the world. Early prevention and control of dyslipidaemia is of paramount importance to reduce the risk of developing CVD. Education of the public and healthcare professionals and developing preventive programs, FH registries and regional guidelines on dyslipidaemia are the keys to dyslipidaemia management in the ME region.

Original languageEnglish
Pages (from-to)182-187
Number of pages6
JournalAtherosclerosis
Volume252
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Middle East
Dyslipidemias
Hyperlipoproteinemia Type II
Cardiovascular Diseases
Preventive Health Services
Marriage
LDL Cholesterol
HDL Cholesterol
Registries
Epidemiology
Triglycerides
Guidelines
Delivery of Health Care
Education
Mortality

Keywords

  • Cardiovascular disease
  • Dyslipidaemia
  • Familial hypercholesterolaemia
  • Guidelines
  • Middle east
  • Prevalence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Al Rasadi, K., Almahmeed, W., AlHabib, K. F., Abifadel, M., Farhan, H. A., AlSifri, S., ... Barter, P. (2016). Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis, 252, 182-187. https://doi.org/10.1016/j.atherosclerosis.2016.07.925

Dyslipidaemia in the Middle East : Current status and a call for action. / Al Rasadi, Khalid; Almahmeed, Wael; AlHabib, Khalid F.; Abifadel, Marianne; Farhan, Hasan Ali; AlSifri, Saud; Jambart, Selim; Zubaid, Mohammad; Awan, Zuhier; Al-Waili, Khalid; Barter, Philip.

In: Atherosclerosis, Vol. 252, 01.09.2016, p. 182-187.

Research output: Contribution to journalReview article

Al Rasadi, K, Almahmeed, W, AlHabib, KF, Abifadel, M, Farhan, HA, AlSifri, S, Jambart, S, Zubaid, M, Awan, Z, Al-Waili, K & Barter, P 2016, 'Dyslipidaemia in the Middle East: Current status and a call for action', Atherosclerosis, vol. 252, pp. 182-187. https://doi.org/10.1016/j.atherosclerosis.2016.07.925
Al Rasadi, Khalid ; Almahmeed, Wael ; AlHabib, Khalid F. ; Abifadel, Marianne ; Farhan, Hasan Ali ; AlSifri, Saud ; Jambart, Selim ; Zubaid, Mohammad ; Awan, Zuhier ; Al-Waili, Khalid ; Barter, Philip. / Dyslipidaemia in the Middle East : Current status and a call for action. In: Atherosclerosis. 2016 ; Vol. 252. pp. 182-187.
@article{7bb3ada3487649bd9d49917efce4f317,
title = "Dyslipidaemia in the Middle East: Current status and a call for action",
abstract = "The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is among the highest in the world. The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its management in the ME region, and to propose initiatives to address the burden of dyslipidaemia. Published literature on the epidemiology of dyslipidaemia in the ME region was presented and discussed at an expert meeting that provided the basis of this review article. The high prevalence of metabolic syndrome, diabetes, familial hypercholesterolaemia (FH) and consanguineous marriages, in the ME region, results in a pattern of dyslipidaemia (low high-density lipoprotein cholesterol and high triglycerides) that is different from many other regions of the world. Early prevention and control of dyslipidaemia is of paramount importance to reduce the risk of developing CVD. Education of the public and healthcare professionals and developing preventive programs, FH registries and regional guidelines on dyslipidaemia are the keys to dyslipidaemia management in the ME region.",
keywords = "Cardiovascular disease, Dyslipidaemia, Familial hypercholesterolaemia, Guidelines, Middle east, Prevalence",
author = "{Al Rasadi}, Khalid and Wael Almahmeed and AlHabib, {Khalid F.} and Marianne Abifadel and Farhan, {Hasan Ali} and Saud AlSifri and Selim Jambart and Mohammad Zubaid and Zuhier Awan and Khalid Al-Waili and Philip Barter",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.atherosclerosis.2016.07.925",
language = "English",
volume = "252",
pages = "182--187",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Dyslipidaemia in the Middle East

T2 - Current status and a call for action

AU - Al Rasadi, Khalid

AU - Almahmeed, Wael

AU - AlHabib, Khalid F.

AU - Abifadel, Marianne

AU - Farhan, Hasan Ali

AU - AlSifri, Saud

AU - Jambart, Selim

AU - Zubaid, Mohammad

AU - Awan, Zuhier

AU - Al-Waili, Khalid

AU - Barter, Philip

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is among the highest in the world. The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its management in the ME region, and to propose initiatives to address the burden of dyslipidaemia. Published literature on the epidemiology of dyslipidaemia in the ME region was presented and discussed at an expert meeting that provided the basis of this review article. The high prevalence of metabolic syndrome, diabetes, familial hypercholesterolaemia (FH) and consanguineous marriages, in the ME region, results in a pattern of dyslipidaemia (low high-density lipoprotein cholesterol and high triglycerides) that is different from many other regions of the world. Early prevention and control of dyslipidaemia is of paramount importance to reduce the risk of developing CVD. Education of the public and healthcare professionals and developing preventive programs, FH registries and regional guidelines on dyslipidaemia are the keys to dyslipidaemia management in the ME region.

AB - The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is among the highest in the world. The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its management in the ME region, and to propose initiatives to address the burden of dyslipidaemia. Published literature on the epidemiology of dyslipidaemia in the ME region was presented and discussed at an expert meeting that provided the basis of this review article. The high prevalence of metabolic syndrome, diabetes, familial hypercholesterolaemia (FH) and consanguineous marriages, in the ME region, results in a pattern of dyslipidaemia (low high-density lipoprotein cholesterol and high triglycerides) that is different from many other regions of the world. Early prevention and control of dyslipidaemia is of paramount importance to reduce the risk of developing CVD. Education of the public and healthcare professionals and developing preventive programs, FH registries and regional guidelines on dyslipidaemia are the keys to dyslipidaemia management in the ME region.

KW - Cardiovascular disease

KW - Dyslipidaemia

KW - Familial hypercholesterolaemia

KW - Guidelines

KW - Middle east

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=84988489464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988489464&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2016.07.925

DO - 10.1016/j.atherosclerosis.2016.07.925

M3 - Review article

C2 - 27522462

AN - SCOPUS:84988489464

VL - 252

SP - 182

EP - 187

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -